Clinical Trials and Study Progress - 71 patients have been dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel), with interim analysis results expected in 1H'25[4] - FDA cleared the IND application for CRG-023, a tri-specific CAR T, with Phase 1 study enrollment expected to initiate mid-year 2025[4] - CRG-023 Phase 1 study will begin at a dose level of 25 million cells, informed by preclinical data showing in vivo tumor clearance at low dose levels[6] - CARGO expects to share topline data from an interim analysis of firi-cel with at least 3 months of follow-up in 1H'25[10] CAR T-Cell Therapy Development - CARGO's novel allogeneic platform is designed to limit immune-based rejection and enable durable response of CAR T-cell therapy, with lead vector candidate selection expected in 1H'25[7] - CRG-023 is a first-of-its-kind CAR T to express three independent CARs (CD19, CD20, CD22) from a single vector, each with a distinct co-stimulatory domain[10] - The novel allogeneic platform aims to transform autologous CAR T-cell therapies into allogeneic products, leveraging existing autologous drug product processes[7] - CRG-023 drug product is produced using CARGO's internally developed process and analytical methods, with a suspension culture process providing commercially suitable expression levels[10] Strategic Plans and Financials - CARGO plans to leverage proof-of-concept data from CRG-023 to support moving quickly into earlier lines of therapy and additional indications in B-cell malignancies[10] - CARGO's preliminary cash, cash equivalents, and marketable securities were $368.1 million as of December 31, 2024, expected to fund operations through 2026[11]

Core Insights - CARGO Therapeutics is advancing multiple clinical-stage programs, including firi-cel and CRG-023, with significant milestones expected in 2025 [1][2][4] Group 1: Clinical Developments - 71 patients have been dosed in the Phase 2 study of firi-cel, with interim analysis results anticipated in the first half of 2025 [1][5] - The FDA has cleared the IND application for CRG-023, a tri-specific CAR T-cell therapy, with Phase 1 study enrollment expected to begin mid-2025 [1][4] - CARGO's CRG-023 is designed to target multiple B-cell malignancies and aims to provide durable complete responses [4][10] Group 2: Novel Allogeneic Platform - CARGO has introduced a novel allogeneic platform utilizing a universal vector to create allogeneic CAR T-cell therapies, addressing limitations of current autologous therapies [1][10] - The allogeneic platform aims to limit immune rejection and enhance the availability of CAR T-cell therapies for patients [10][11] - Preclinical results suggest the potential for off-the-shelf allogeneic CAR T products, which could improve patient access to life-saving therapies [2][10] Group 3: Financial Outlook - As of December 31, 2024, CARGO reported preliminary cash, cash equivalents, and marketable securities totaling $368.1 million, expected to fund operations through 2026 [8][11] - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [8]

SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California. Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 13, at 10:30 a.m. ...

CARGO Therapeutics, Inc. (CRGX) has been on a downward spiral lately with significant selling pressure. After declining 14.1% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting ...

A downtrend has been apparent in CARGO Therapeutics, Inc. (CRGX) lately. While the stock has lost 5.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the fu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-41859 CARGO Therapeutics, Inc. (Exact Name of Registrant as Specified in its ...

Exhibit 99.1 CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - 57 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel); on track for interim analysis in 1H25 - - CRG-023 pre-clinical data to be presented at ASH 2024; IND submission anticipated Q1'25 with Phase 1 initiation planned for 2025 - - Anup Radhakrishnan, CFO of CARGO Therapeutics, appointed as COO and CFO - SAN CARLOS, Calif., November 12, 2024 ...

Along with quarterly results, the clinical-stage company provided an encouraging business update. This was a good week to be invested in clinical-stage biotech Cargo Therapeutics (CRGX 1.04%). The company dropped its second-quarter earnings release, and investors were quite cheered by the progress the business is making. They also liked that its net loss for the period wasn't as deep as analysts expected. Across the five trading days, Cargo's stock price rose by just under 19%, according to data compiled by ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-41859 CARGO Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 84-40 ...

Exhibit 99.1 CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., August 12, 2024 – CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, poten ...